For the first time, experts at Hiroshima University and Kobe University developed a biomarker for the detection of Parkinson’s disease (PD) in blood samples.
According to the study in Scientific Reports, “Previously, we developed a cytochrome P450 inhibition assay that detects alterations in metabolite levels associated with P450s caused by inflammation and exposure to endogenous or exogenous substances.”
“However, it is unknown whether the P450 inhibition assay can be applied in PD diagnosis. Here, we determined whether the P450 inhibition assay can discriminate sera between patients with PD and healthy individuals.”
The study showed that the P450 inhibition assay can help lead to the future outset of liquid biopsy-based diagnostic methods for Parkinson’s disease.
“The results of these experiments revealed that the P450 inhibition assay is potentially applicable for the diagnosis of patients with PD.”